HGF/MET positive modulators reduce pain-related behaviors in a model of diabetic neuropathy
BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve Society (PNS) Annual Meeting.

The research highlights the effect of ATH-1018 and ATH-1019 on neuropathic pain-related behaviors in a preclinical model of streptozotocin (STZ)-induced diabetic neuropathy. Data demonstrate that measures of pain-related behaviors were significantly improved on testing days across all dose levels for each molecule. Pain-related behaviors were also significantly reduced prior to dosing on day 25 when ATH-1018 or ATH-1019 had been cleared from plasma, suggestive of potentially persistent pain-modifying effects.
“Previous work has identified the HGF/MET pathway as a potential therapeutic target for peripheral neuropathies, including diabetic neuropathy, which features components of nerve damage and inflammation. Our preclinical data demonstrates the potential of ATH-1018 and ATH-1019 as therapeutic candidates for painful diabetic neuropathy,” said Kevin Church, Ph.D., Executive Vice President, Research of Athira. “We look forward to the continued evaluation of these candidates to further support our pipeline expansion.”
The poster “Small Molecule HGF/MET Positive Modulator Effectively Reduces Pain-Related Behaviors in a Rat Diabetic Neuropathy Model” can be found on the Scientific Publications & Presentations page of the company’s website at www.athira.com. The poster is also viewable on the PNS conference website to registrants through Dec. 31, 2022.
About Athira Pharma, Inc.
Athira Pharma Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline therapeutic candidates, targeting the HGF/MET neurotrophic system, for Alzheimer’s and Parkinson’s disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding Athira’s product candidates, including ATH-1018 and ATH-1019 as therapeutic candidates for peripheral diabetic neuropathy; Athira’s platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; expectations regarding the potential efficacy and commercial potential of Athira’s product candidates; the anticipated reporting of data; and Athira’s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” and other similar expressions, among others. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira’s product candidates will not continue or persist in current or planned clinical trials; cessation or delay of any of the ongoing clinical trials and/or Athira’s development of ATH-1018, ATH-1019 and other product candidates may occur; future potential regulatory milestones of ATH-1018 and ATH-1019 and other product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira’s business, research and clinical development plans and timelines, and results of operations, including impact on Athira’s clinical trial sites and contractors who act for or on Athira’s behalf, may be more severe and more prolonged than currently anticipated; the regulatory process for Athira product candidates; the outcome of legal proceedings which have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira’s product candidates; Athira’s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira’s product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira’s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; Athira’s assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; as well as the other risks detailed in Athira’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
[email protected]

Related Quotes
Along with keeping up with healthy daily habits, sometimes in an attempt to help our bodies steer clear of the unwanted disease in the later years of our lives, doctors recommend taking a set of supplements for our health. However, a recent study found that the dietary supplement L-serine, an essential compound that influences brain functionality, may cause a cognitive decline in some adults.L-serine is a naturally occurring amino acid that is made up within the body and is most necessary for pr
Dementia is one of the scariest risks associated with aging, affecting nearly 5.6 million Americans over the age of 65, per the Centers for Disease Control and Prevention (CDC). Currently, there is no cure for any kind of dementia, including the most common form, Alzheimer's disease. Researchers and health experts work to help those who already have the condition, while simultaneously trying to understand how the disease presents itself—and what can be done to stave it off. One recent study poin
All it takes is eating a cupful of cranberries everyday to potentially prevent dementia, and other health benefits.
There’s a lot of debate about when it makes sense to invest in a traditional or Roth IRA. Investments across sectors are not performing well thanks to market volatility, but some investors may be more worried than others. Leaving the workforce early may sound like a great idea, but consider its impact on Social Security later in life.
Pimco executive Dan Ivascyn discusses inflation, interest rates, where he sees risks. Where he’s finding high-quality yields.
From meme-stock enthusiasts to retirees, this year's steep dive for both stocks and U.S. Treasury prices has upended portfolios for individual investors who had enjoyed watching their wealth grow during the historic rally in financial assets early in the coronavirus pandemic in 2020. That strategy does not work when stocks and bonds fall in unison.
The market ignored poor earnings and guidance from Walmart on Tuesday as strength in technology stocks encouraged traders that were looking for a sustained counter-trend bounce. Bids totally disappeared, and the indexes suffered their worst action of the year. Pundits in the business media proclaimed that this is some of the worst action that they have seen, but if we dig a bit deeper, it appears that it was big-cap stocks and the indexes that suffered to a much greater degree than many secondary stocks.
GLNG stock, the IBD Stock of the Day, is finding support at a key level, ahead of first-quarter earnings due on Thursday.
The maker of semiconductor equipment reported sales and earnings below analyst estimates, sending shares lower after hours.
European Union officials are proposing a ban on insuring ships that transport Russian oil as part of sanctions on Russia for its invasion of Ukraine.
China has long been considered an essential component of Tesla’s (TSLA) ongoing success. The country has not only been committed to advancing electric vehicles, but is also home to its flagship Gigafactory, located in Shanghai. Wedbush’s Daniel Ives has repeatedly stressed the region’s importance to Tesla and thinks the current China headwinds are “hard to ignore.” “The success of the China story on both the supply and demand side are the linchpins to our long-term bull thesis in Tesla,” the 5-s
(Bloomberg) — Amazon.com Inc. is testing a service that uses the company’s sprawling network of gig drivers to fetch packages from mall-based retailers and deliver them to customers. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesStocks Avert Bear Market, Slide for Seventh Week: Markets WrapApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Cr
(Bloomberg) — The pros are buried in it. But how deeply is the falling market burrowing into consumer psyches? It’s an urgent question for policy makers trying to subdue inflation while guiding the economy to a soft landing.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightTarget and Walmart’s Deep Pain Could Be Your GainWalmart Flashes a Warning Sign to the Entire Consumer EconomyApple Shows AR/VR Headset to Board in Sign of Progress
Bitcoin lost support at $30,000 as Chinese technology stocks sold off on Thursday amid earnings worries a day after hawkish comments from the U.S. Federal Reserve.
Stock market declines broaden as other sectors join retailers. Deere stock falls in spite of earnings beat.
The Boston-based firm intends to build a 200,000-square-foot good manufacturing practice, or GMP, plant on the property.
Reckoning they have little to lose with prices so ridiculously low, South Korean speculators in recent days have piled into Luna, a cryptocurrency that lost 99.99% of its value last week after its paired stablecoin TerraUSD collapsed. Both tokens are affiliated with Terra, a blockchain platform co-founded by Korean developer Do Kwon and, according to blockchain analytics firm Elliptic, investors in them have lost around $42 billion. Luna had been one of the world's most popular cryptocurrencies and its downfall, alongside TerraUSD, caused mayhem across the crypto spectrum globally, with bitcoin losing around a quarter of its value between May 9-12.
(Bloomberg) — Oil rose in a choppy trading session as equity markets pared losses, shrugging off concerns of an economic recession.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightChina in Talks With Russia to Buy Oil for Strategic ReservesApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Target and Walmart’s Deep Pain Could Be Your GainWalmart Flashes a Warning Sign to the Entire Consumer EconomyWest Texas Interme
(Bloomberg) — Tether, the operator of the world’s most used cryptocurrency, said it had reduced the amount of commercial paper in the reserve backing its $74 billion stablecoin, revealing information about its holdings while dollar-pegged assets face tougher scrutiny from regulators.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightChina in Talks With Russia to Buy Oil for Strategic ReservesApple Shows AR/VR Headset to Board in Sign of
What if I told you that equity markets sold off almost by accident on Thursday? The S&P 500 had given up another 0.58%, while the Nasdaq Composite surrendered a mere 0.26%. The session's final score left the major indexes on the doorstep of a seventh consecutive "down" week, which would be the longest weekly losing streak for the S&P 500 in particular since 2001.


Published On: May 21, 2022 / Categories: Uncategorized /

Subscribe To Receive The Latest News

Stay upto date with latest developments

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

Add notice about your Privacy Policy here.